January 21, 2025

Only 2% of Eligible Patients Get New Obesity Drug

"These findings suggest that inequities persist in medication access in this understudied subgroup."

Conexiant

January 21, 2025

Pancreatic Enzymes and Autoantibodies Signal T1D Progression

Lipase and trypsinogen levels were differentially informative for distinguishing clinical groups in type 1 diabetes, researchers reported.

Conexiant

January 21, 2025

Urinary Prostaglandins vs Calprotectin in IBD

Explore the latest study comparing urinary prostaglandin metabolites to fecal calprotectin for monitoring Crohn’s disease and ulcerative colitis activity.

Conexiant

January 21, 2025

ASCO Thanks Drs. Bertagnolli, Rathmell for Their Service Leading NIH, NCI

ASCO has applauded Monica M. Bertagnolli, MD, FACS, FASCO, and Kimryn Rathmell, MD, PhD, for their service as the 17th Director of the National Institutes of Health (NIH) and the 17th Director of the ...

The ASCO Post

January 21, 2025

Large Study Links eGFR to Brain Structural Changes

"This study highlights the link between reduced eGFR, cognitive impairment, and brain structure, revealing some of the kidney-brain axis mechanisms."

Conexiant

January 17, 2025

Predictive Model for Difficult Psoriatic Arthritis Treatment

"According to the predictive model, the proposed D2T PsA definition identified a small subset of patients with increased treatment difficulty. These findings highlight the need for refining the criteria to better define D2T PsA patients."

Conexiant

January 16, 2025

Vertigo, Emesis, Auditory Impairment: What's Your Diagnosis?

A patient presents with sudden-onset right-sided otalgia accompanied by vertigo, emesis, and auditory impairment. Your otoscope reveals an unexpected finding. What's your diagnosis?

Conexiant

January 16, 2025

Adjuvant T-DM1 in Patients With HER2-Positive Breast Cancer: Long-Term Results of the KATHERINE Trial

Adjuvant treatment with an antibody-drug conjugate (ADC) may improve survival in patients with high-risk HER2-positive breast cancer and residual invasive disease.

The ASCO Post

January 16, 2025

Study: Baloxavir Shows Promise in Nonsevere Influenza

Baloxavir probably reduced risk of hospital admission for high-risk patients and may reduce time to alleviation of symptoms, without increasing adverse events related to treatment in patients with nonsevere influenza," finds comprehensive network meta-analysis of 73 trials involving 34,332 participants.

Conexiant